Abstract
Arsenic trioxide has recently been reported to be successful in the treatment of promyelocytic leukemia. Several concerns about the use of this toxic agent are currently reducing its potential clinical use even in severely ill patients. In this report we describe the results achieved by As2O3 with all-trans retinoic acid in a patient suffering from secondary, relapsed, resistant promyelocytic leukemia. Several complications, including sepsis and an extensive area of skin necrosis, did not allow us to treat the patient further with chemotherapy. With As2O3 and ATRA therapy, the patient obtained a complete molecular remission without any significant toxicity and, subsequently, it was possible to perform a bone marrow autograft in a state of complete remission.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Galimberti, S., Papineschi, F., Carmignani, A. et al. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone Marrow Transplant 24, 345–348 (1999). https://doi.org/10.1038/sj.bmt.1701875
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701875
Keywords
This article is cited by
-
Successful Unrelated Bone Marrow Transplantation After Arsenic Trioxide Treatment in a Patient With Relapsed Acute Promyelocytic Leukemia
International Journal of Hematology (2002)
-
Arsenic trioxide, a therapeutic agent for APL
Oncogene (2001)
-
The role of bone marrow transplantation in acute promyelocytic leukemia
Bone Marrow Transplantation (2001)